Aims Lenvatinib is an oral multi-kinase inhibitor approved for the treatment of adults with
progressive, locally advanced or metastatic, differentiated thyroid carcinoma refractory to …

Introduction: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor of VEGFR1, 2, 3, 4,
FGFR1, 2, 3, 4, PDGFR-α as well as RET and KIT signaling network. Its activity against …

Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …

Purpose In the study of (E7080) lenvatinib in differentiated cancer of the thyroid, most
patients experienced an adverse event. In this report, we examine common lenvatinib …

Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved
in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and …

Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …

ABSTRACT Lenvatinib mesylate (E7080; 4-[3-chloro-4-(N′-cyclopropylureido) phenoxy] 7-
methoxyquinoline-6-carboxamide mesylate) is an oral molecule that inhibits multiple …

Context The SELECT trial led to the approval of lenvatinib for the treatment of advanced
radioiodine-refractory differentiated thyroid carcinomas (DTCs) but also revealed an …

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.
Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory …

Objective: Lenvatinib is approved for use in advanced radioactive iodine-resistant
differentiated thyroid cancers (RAIR-DTCs). Its efficacy is indisputable, but toxicities are …